Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas, Osaka University Join Hands in Cell Therapy Research
July 23, 2024
- MSD Seeks Japan Nod for RCC Med Belzutifan
July 23, 2024
- Mochida Files Pediatric Dosage of UC Drug Lialda in Japan
July 23, 2024
- Chugai to Offload Hyperammonemia Drug to Maruishi
July 23, 2024
- Terumo to End Sale of HeartSheet after Panel’s Thumbs-Down
July 22, 2024
- Deciphera’s TGCT Drug Accepted for Review in Europe: Ono
July 22, 2024
- FDA Clears IND for Japan JV’s Peptide-Based COVID Therapy
July 19, 2024
- Opdivo Extends Label for Frontline Bladder Cancer in South Korea
July 19, 2024
- Renalys Raises 6 Billion Yen in Series A Financing to Push IgA Med
July 18, 2024
- BMS Files Hypertrophic Cardiomyopathy Drug in Japan
July 18, 2024
- Eisai Hands Over Fosravuconazole Rights in Asia/Oceania to Sato
July 17, 2024
- Kissei Clears Primary Goal for Linzagolix in Japan PIII
July 17, 2024
- Sumitomo Nabs FDA’s Fast-Track Tag for Cancer Med DSP-5336
July 17, 2024
- Insmed Set to Double Japan Staff by 2025-End as It Gears Up for Brensocatib Debut
July 17, 2024
- Senju/Mochida's Dry Eye Med Scores PIII Primary Endpoint
July 17, 2024
- LTL, Cheplapharm Envision Heightened Opportunities for LLP Takeovers under Elective Care Scheme
July 16, 2024
- Meiji Paints Consortium Plan of Its Own, Woos Generic Peers to Join Scheme
July 16, 2024
- Shonan iPark Commences Full-Fledged Operations in South Korea
July 16, 2024
- Ex-Teva Takeda Chief Matsumori to Lead Daito
July 16, 2024
- AbbVie Files Venclexta for Mantle Cell Lymphoma in Japan
July 16, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…